Cargando…

Convalescent plasma is of limited clinical benefit in critically ill patients with coronavirus disease-2019: a cohort study

BACKGROUND: Recently, convalescent plasma (CP) transfusion was employed for severe or critically ill patients with coronavirus disease-2019. However, the benefits of CP for patients with different conditions are still in debate. To contribute clinical evidence of CP on critically ill patients, we an...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Li, Zhang, Che, Zhou, Xihui, Zhao, Zhou, Wang, Weiping, Leng, Weidong, Su, Xiao, Lian, Qizhou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8390032/
https://www.ncbi.nlm.nih.gov/pubmed/34446049
http://dx.doi.org/10.1186/s12967-021-03028-5
_version_ 1783743004104720384
author Huang, Li
Zhang, Che
Zhou, Xihui
Zhao, Zhou
Wang, Weiping
Leng, Weidong
Su, Xiao
Lian, Qizhou
author_facet Huang, Li
Zhang, Che
Zhou, Xihui
Zhao, Zhou
Wang, Weiping
Leng, Weidong
Su, Xiao
Lian, Qizhou
author_sort Huang, Li
collection PubMed
description BACKGROUND: Recently, convalescent plasma (CP) transfusion was employed for severe or critically ill patients with coronavirus disease-2019. However, the benefits of CP for patients with different conditions are still in debate. To contribute clinical evidence of CP on critically ill patients, we analyze the characteristics and outcomes of patients with or without CP transfusion. METHODS: In this cohort study, 14 patients received CP transfusion based on the standard treatments, whereas the other 10 patients received standard treatments as control. Clinical characteristics and outcomes were analyzed. The cumulative survival rate was calculated by Kaplan–Meier survival analysis. RESULTS: Data analysis was performed on 24 patients (male/female: 15/9) with a median age of 64.0 (44.5–74.5) years. Transient fever was reported in one patient. The cumulative mortality was 21% (3/14) in patients receiving CP transfusion during a 28-day observation, whereas one dead case (1/10) was reported in the control group. No significant difference was detected between groups in 28-day mortality (P = 0.615) and radiological alleviation of lung lesions (P = 0.085). CONCLUSION: In our current study, CP transfusion was clinically safe based on the safety profile; however, the clinical benefit was not significant in critically ill patients with more comorbidities at the late stage of disease during a 28-day observation. GRAPHIC ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-021-03028-5.
format Online
Article
Text
id pubmed-8390032
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-83900322021-08-27 Convalescent plasma is of limited clinical benefit in critically ill patients with coronavirus disease-2019: a cohort study Huang, Li Zhang, Che Zhou, Xihui Zhao, Zhou Wang, Weiping Leng, Weidong Su, Xiao Lian, Qizhou J Transl Med Research BACKGROUND: Recently, convalescent plasma (CP) transfusion was employed for severe or critically ill patients with coronavirus disease-2019. However, the benefits of CP for patients with different conditions are still in debate. To contribute clinical evidence of CP on critically ill patients, we analyze the characteristics and outcomes of patients with or without CP transfusion. METHODS: In this cohort study, 14 patients received CP transfusion based on the standard treatments, whereas the other 10 patients received standard treatments as control. Clinical characteristics and outcomes were analyzed. The cumulative survival rate was calculated by Kaplan–Meier survival analysis. RESULTS: Data analysis was performed on 24 patients (male/female: 15/9) with a median age of 64.0 (44.5–74.5) years. Transient fever was reported in one patient. The cumulative mortality was 21% (3/14) in patients receiving CP transfusion during a 28-day observation, whereas one dead case (1/10) was reported in the control group. No significant difference was detected between groups in 28-day mortality (P = 0.615) and radiological alleviation of lung lesions (P = 0.085). CONCLUSION: In our current study, CP transfusion was clinically safe based on the safety profile; however, the clinical benefit was not significant in critically ill patients with more comorbidities at the late stage of disease during a 28-day observation. GRAPHIC ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-021-03028-5. BioMed Central 2021-08-26 /pmc/articles/PMC8390032/ /pubmed/34446049 http://dx.doi.org/10.1186/s12967-021-03028-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Huang, Li
Zhang, Che
Zhou, Xihui
Zhao, Zhou
Wang, Weiping
Leng, Weidong
Su, Xiao
Lian, Qizhou
Convalescent plasma is of limited clinical benefit in critically ill patients with coronavirus disease-2019: a cohort study
title Convalescent plasma is of limited clinical benefit in critically ill patients with coronavirus disease-2019: a cohort study
title_full Convalescent plasma is of limited clinical benefit in critically ill patients with coronavirus disease-2019: a cohort study
title_fullStr Convalescent plasma is of limited clinical benefit in critically ill patients with coronavirus disease-2019: a cohort study
title_full_unstemmed Convalescent plasma is of limited clinical benefit in critically ill patients with coronavirus disease-2019: a cohort study
title_short Convalescent plasma is of limited clinical benefit in critically ill patients with coronavirus disease-2019: a cohort study
title_sort convalescent plasma is of limited clinical benefit in critically ill patients with coronavirus disease-2019: a cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8390032/
https://www.ncbi.nlm.nih.gov/pubmed/34446049
http://dx.doi.org/10.1186/s12967-021-03028-5
work_keys_str_mv AT huangli convalescentplasmaisoflimitedclinicalbenefitincriticallyillpatientswithcoronavirusdisease2019acohortstudy
AT zhangche convalescentplasmaisoflimitedclinicalbenefitincriticallyillpatientswithcoronavirusdisease2019acohortstudy
AT zhouxihui convalescentplasmaisoflimitedclinicalbenefitincriticallyillpatientswithcoronavirusdisease2019acohortstudy
AT zhaozhou convalescentplasmaisoflimitedclinicalbenefitincriticallyillpatientswithcoronavirusdisease2019acohortstudy
AT wangweiping convalescentplasmaisoflimitedclinicalbenefitincriticallyillpatientswithcoronavirusdisease2019acohortstudy
AT lengweidong convalescentplasmaisoflimitedclinicalbenefitincriticallyillpatientswithcoronavirusdisease2019acohortstudy
AT suxiao convalescentplasmaisoflimitedclinicalbenefitincriticallyillpatientswithcoronavirusdisease2019acohortstudy
AT lianqizhou convalescentplasmaisoflimitedclinicalbenefitincriticallyillpatientswithcoronavirusdisease2019acohortstudy